Certara, Inc. (NASDAQ:CERT) Receives Average Rating of “Hold” from Analysts

Posted by George Bondi on May 30th, 2026

Shares of Certara, Inc. (NASDAQ:CERT – Get Free Report) have been assigned a consensus recommendation of “Hold” from the thirteen research firms that are covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, six have given a hold recommendation, five have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $8.85.

Several brokerages recently commented on CERT. Barclays dropped their price objective on Certara from $8.00 to $6.50 and set an “equal weight” rating on the stock in a research note on Tuesday, May 12th. Morgan Stanley dropped their price objective on Certara from $11.00 to $10.00 and set an “equal weight” rating on the stock in a research note on Tuesday, May 12th. Leerink Partners reaffirmed an “outperform” rating and set a $10.00 price objective on shares of Certara in a research note on Thursday, February 26th. KeyCorp dropped their price target on Certara from $10.00 to $8.00 and set an “overweight” rating on the stock in a research note on Monday, April 13th. Finally, Craig Hallum dropped their price target on Certara from $10.00 to $8.00 and set a “hold” rating on the stock in a research note on Tuesday, May 12th.

Read Our Latest Research Report on CERT

Institutional Trading of Certara

Several hedge funds and other institutional investors have recently modified their holdings of the company. Bank of America Corp DE raised its stake in shares of Certara by 292.2% in the 1st quarter. Bank of America Corp DE now owns 2,042,946 shares of the company’s stock valued at $11,645,000 after purchasing an additional 1,522,034 shares during the period. The Manufacturers Life Insurance Company raised its stake in shares of Certara by 12.1% in the 1st quarter. The Manufacturers Life Insurance Company now owns 23,289 shares of the company’s stock valued at $133,000 after purchasing an additional 2,513 shares during the period. Quantinno Capital Management LP raised its stake in shares of Certara by 412.5% in the 1st quarter. Quantinno Capital Management LP now owns 988,990 shares of the company’s stock valued at $5,637,000 after purchasing an additional 796,007 shares during the period. SummitTX Capital L.P. acquired a new stake in shares of Certara in the 1st quarter valued at about $219,000. Finally, Entropy Technologies LP acquired a new stake in shares of Certara in the 1st quarter valued at about $201,000. Institutional investors and hedge funds own 73.96% of the company’s stock.

Certara Stock Performance

Shares of Certara stock opened at $5.82 on Friday. The company has a market capitalization of $905.42 million, a PE ratio of -58.20 and a beta of 1.53. Certara has a 12 month low of $4.45 and a 12 month high of $13.88. The company has a current ratio of 1.88, a quick ratio of 1.88 and a debt-to-equity ratio of 0.28. The stock’s fifty day simple moving average is $5.69 and its 200 day simple moving average is $7.39.

Certara (NASDAQ:CERT – Get Free Report) last issued its quarterly earnings data on Monday, May 11th. The company reported $0.09 EPS for the quarter, missing the consensus estimate of $0.11 by ($0.02). The business had revenue of $106.92 million for the quarter, compared to analyst estimates of $106.13 million. Certara had a positive return on equity of 3.52% and a negative net margin of 3.60%.The business’s quarterly revenue was up .8% compared to the same quarter last year. During the same period in the previous year, the business posted $0.14 EPS. Certara has set its FY 2026 guidance at 0.350-0.410 EPS. On average, research analysts predict that Certara will post 0.24 EPS for the current year.

About Certara

(Get Free Report)

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.